{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:25:36Z","timestamp":1788175536332,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anhui Provincial Key Research and Development Program of Traditional Chinese Medicine","award":["202303a07020009"],"award-info":[{"award-number":["202303a07020009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11095-026-04092-6","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:11:15Z","timestamp":1775661075000},"page":"1425-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-219X","authenticated-orcid":false,"given":"Jiajia","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyun","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"5","key":"4092_CR1","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.21037\/jtd-21-609","volume":"13","author":"LJ Li","year":"2021","unstructured":"Li LJ, Gu YJ, Wang LQ, Wan W, Wang HW, Yang XN, et al. Serum exosomal microRNA-146a as a novel diagnostic biomarker for acute coronary syndrome. J Thorac Dis. 2021;13(5):3105\u201314. https:\/\/doi.org\/10.21037\/jtd-21-609.","journal-title":"J Thorac Dis"},{"issue":"9","key":"4092_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091147","volume":"15","author":"BM Alomair","year":"2022","unstructured":"Alomair BM, Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier JM, et al. Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals (Basel). 2022;15(9):1147. https:\/\/doi.org\/10.3390\/ph15091147.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"4092_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/emj.2008.064428","volume":"26","author":"S Goodacre","year":"2009","unstructured":"Goodacre S, Pett P, Arnold J, Chawla A, Hollingsworth J, Roe D, et al. Clinical diagnosis of acute coronary syndrome in patients with chest pain and a normal or non-diagnostic electrocardiogram. Emerg Med J. 2009;26(12):866\u201370. https:\/\/doi.org\/10.1136\/emj.2008.064428.","journal-title":"Emerg Med J"},{"issue":"14","key":"4092_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144205","volume":"11","author":"AA Mangoni","year":"2022","unstructured":"Mangoni AA, Zinellu A. Serum concentrations of ischaemia-modified albumin in acute coronary syndrome: a systematic review and meta-analysis. J Clin Med. 2022;11(14):4205. https:\/\/doi.org\/10.3390\/jcm11144205.","journal-title":"J Clin Med"},{"issue":"7","key":"4092_CR5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/jama.2022.0358","volume":"327","author":"DL Bhatt","year":"2022","unstructured":"Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662\u201375. https:\/\/doi.org\/10.1001\/jama.2022.0358.","journal-title":"JAMA"},{"issue":"3","key":"4092_CR6","doi-asserted-by":"publisher","first-page":"I17","DOI":"10.1002\/clc.20363","volume":"31","author":"E Braunwald","year":"2008","unstructured":"Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008;31(3):I17-20. https:\/\/doi.org\/10.1002\/clc.20363.","journal-title":"Clin Cardiol"},{"issue":"10","key":"4092_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jacc.2019.12.067","volume":"75","author":"BM Scirica","year":"2020","unstructured":"Scirica BM, Bergmark BA, Morrow DA, Antman E, Bonaca MP, Murphy SA, et al. Nonculprit lesion myocardial infarction following percutaneous coronary intervention in patients with acute\u00a0coronary syndrome. J Am Coll Cardiol. 2020;75(10):1095\u2013106. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.067.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4092_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076709","volume":"24","author":"P Entsie","year":"2023","unstructured":"Entsie P, Kang Y, Amoafo EB, Sch\u00f6neberg T, Liverani E. The signaling pathway of the ADP receptor P2Y12\u00a0in the immune system: recent discoveries and new challenges. Int J Mol Sci. 2023;24(7):6709. https:\/\/doi.org\/10.3390\/ijms24076709.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"4092_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/jama.2021.0716","volume":"325","author":"H Kamran","year":"2021","unstructured":"Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021;325(15):1545\u201355. https:\/\/doi.org\/10.1001\/jama.2021.0716.","journal-title":"JAMA"},{"issue":"1","key":"4092_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00568-3","volume":"18","author":"LQ Khasawneh","year":"2024","unstructured":"Khasawneh LQ, Alsafar H, Alblooshi H, Allam M, Patrinos GP, Ali BR. The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population. Hum Genomics. 2024;18(1):2. https:\/\/doi.org\/10.1186\/s40246-023-00568-3.","journal-title":"Hum Genomics"},{"issue":"5","key":"4092_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19158977","volume":"19","author":"A Pradhan","year":"2022","unstructured":"Pradhan A, Tiwari A, Caminiti G, Salimei C, Muscoli S, Sethi R, et al. Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status. Int J Environ Res Public Health. 2022;19(5):8977. https:\/\/doi.org\/10.3390\/ijerph19158977.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4092_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/fjc.0b013e3181dd0ec2","volume":"56","author":"JA Jakubowski","year":"2010","unstructured":"Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, et al. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol. 2010;56(1):29\u201337. https:\/\/doi.org\/10.1097\/fjc.0b013e3181dd0ec2.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"4092_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/circinterventions.112.972323","volume":"5","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797\u2013804. https:\/\/doi.org\/10.1161\/circinterventions.112.972323.","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"4092_CR14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","volume":"54","author":"R Teng","year":"2015","unstructured":"Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 2015;54(11):1125\u201338. https:\/\/doi.org\/10.1007\/s40262-015-0290-2.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4092_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamacardio.2021.2228","volume":"6","author":"JJ Coughlan","year":"2021","unstructured":"Coughlan JJ, Aytekin A, Lahu S, Ndrepepa G, Menichelli M, Mayer K, et al. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021;6(10):1121\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2021.2228.","journal-title":"JAMA Cardiol"},{"issue":"15","key":"4092_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.024.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4092_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013218","volume":"7","author":"P Adamski","year":"2017","unstructured":"Adamski P, Ostrowska M, Sikora J, Obo\u0144ska K, Buszko K, Krintus M, et al. Comparison of ticagrelor pharmacokinetics and pharmacodynamics in STEMI and NSTEMI patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open. 2017;7(4):e013218. https:\/\/doi.org\/10.1136\/bmjopen-2016-013218.","journal-title":"BMJ Open"},{"issue":"2","key":"4092_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40268-013-0018-4","volume":"13","author":"B Crean","year":"2013","unstructured":"Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Drugs R D. 2013;13(2):153\u20137. https:\/\/doi.org\/10.1007\/s40268-013-0018-4.","journal-title":"Drugs R D"},{"issue":"13","key":"4092_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.022125","volume":"10","author":"L De Luca","year":"2021","unstructured":"De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc. 2021;10(13):e022125. https:\/\/doi.org\/10.1161\/jaha.121.022125.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"4092_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"SR Steinhubl","year":"2008","unstructured":"Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121(4):527\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2007.05.020.","journal-title":"Thromb Res"},{"key":"4092_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.663170","volume":"12","author":"K Buszko","year":"2021","unstructured":"Buszko K, Kubica K, Hobl EL, Adamski P, Wnuk K, Jilma B. Pharmacokinetic modeling of morphine\u2019s effect on plasma concentrations of ticagrelor and its metabolite in healthy volunteers. Front Physiol. 2021;12:663170. https:\/\/doi.org\/10.3389\/fphys.2021.663170.","journal-title":"Front Physiol"},{"issue":"9","key":"4092_CR22","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1124\/dmd.111.039834","volume":"39","author":"Q Sun","year":"2011","unstructured":"Sun Q, Harper TW, Dierks EA, Zhang L, Chang S, Rodrigues AD, et al. 1-aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab Dispos. 2011;39(9):1674\u20139. https:\/\/doi.org\/10.1124\/dmd.111.039834.","journal-title":"Drug Metab Dispos"},{"key":"4092_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108871","volume":"315","author":"YQ Wang","year":"2020","unstructured":"Wang YQ, Shang XF, Wang L, Zhang P, Zou LW, Song YQ, et al. Interspecies variation of clopidogrel hydrolysis in liver microsomes from various mammals. Chem Biol Interact. 2020;315:108871. https:\/\/doi.org\/10.1016\/j.cbi.2019.108871.","journal-title":"Chem Biol Interact"},{"issue":"8","key":"4092_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph13080177","volume":"13","author":"N Wolska","year":"2020","unstructured":"Wolska N, Kassassir H, Luzak B, Watala C, Rozalski M. Adenosine receptor agonists increase the inhibition of platelet function by P2Y12\u00a0antagonists in a cAMP- and calcium-dependent manner. Pharmaceuticals (Basel). 2020;13(8):177. https:\/\/doi.org\/10.3390\/ph13080177.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4092_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/194927b0","volume":"194","author":"GV Born","year":"1962","unstructured":"Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927\u20139. https:\/\/doi.org\/10.1038\/194927b0.","journal-title":"Nature"},{"issue":"7","key":"4092_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315069121","volume":"121","author":"AK MacLeod","year":"2024","unstructured":"MacLeod AK, Coquelin KS, Huertas L, Simeons FRC, Riley J, Casado P, et al. Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism. Proc Natl Acad Sci U S A. 2024;121(7):e2315069121. https:\/\/doi.org\/10.1073\/pnas.2315069121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4092_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.655659","volume":"12","author":"YQ Song","year":"2021","unstructured":"Song YQ, He RJ, Pu D, Guan XQ, Shi JH, Li YG, et al. Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2. Front Pharmacol. 2021;12:655659. https:\/\/doi.org\/10.3389\/fphar.2021.655659.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4092_CR28","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1016\/j.bmcl.2012.04.050","volume":"22","author":"H Zhang","year":"2012","unstructured":"Zhang H, Liu J, Zhang L, Kong L, Yao H, Sun H. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents. Bioorg Med Chem Lett. 2012;22(11):3598\u2013602. https:\/\/doi.org\/10.1016\/j.bmcl.2012.04.050.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"4092_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bph.12108","volume":"169","author":"A Sugidachi","year":"2013","unstructured":"Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013;169(1):82\u20139. https:\/\/doi.org\/10.1111\/bph.12108.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4092_CR30","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.thromres.2012.07.021","volume":"130","author":"A Ravnefjord","year":"2012","unstructured":"Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res. 2012;130(4):622\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2012.07.021.","journal-title":"Thromb Res"},{"issue":"18","key":"4092_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30183733","volume":"30","author":"S Xia","year":"2025","unstructured":"Xia S, Hirao H. Recent advances in elucidating the mechanism of the NADPH-cytochrome P450 reductase-mediated electron transfer cycle: experimental and computational perspectives. Molecules. 2025;30(18):3733. https:\/\/doi.org\/10.3390\/molecules30183733.","journal-title":"Molecules"},{"issue":"11","key":"4092_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","volume":"81","author":"M Taketani","year":"2007","unstructured":"Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci. 2007;81(11):924\u201332. https:\/\/doi.org\/10.1016\/j.lfs.2007.07.026.","journal-title":"Life Sci"},{"issue":"7","key":"4092_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1124\/dmd.115.068957","volume":"44","author":"RN Hines","year":"2016","unstructured":"Hines RN, Simpson PM, McCarver DG. Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny. Drug Metab Dispos. 2016;44(7):959\u201366. https:\/\/doi.org\/10.1124\/dmd.115.068957.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"4092_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/eurheartj\/ehad876","volume":"45","author":"P Capranzano","year":"2024","unstructured":"Capranzano P, Moliterno D, Capodanno D. Aspirin-free antiplatelet strategies after percutaneous coronary interventions. Eur Heart J. 2024;45(8):572\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehad876.","journal-title":"Eur Heart J"},{"key":"4092_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.amjcard.2023.07.014","volume":"204","author":"I Shafi","year":"2023","unstructured":"Shafi I, Patel DA, Osman H, Patel N, Ramaseshan K, Goel M, et al. Outcomes of intravascular ultrasound-guided percutaneous coronary intervention among patients with acute coronary syndrome. Am J Cardiol. 2023;204:115\u201321. https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.014.","journal-title":"Am J Cardiol"},{"issue":"7498","key":"4092_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature13288","volume":"509","author":"J Zhang","year":"2014","unstructured":"Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014;509(7498):119\u201322. https:\/\/doi.org\/10.1038\/nature13288.","journal-title":"Nature"},{"issue":"4","key":"4092_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703\u201310. https:\/\/doi.org\/10.1124\/dmd.110.037143.","journal-title":"Drug Metab Dispos"},{"key":"4092_CR38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18109","volume":"12","author":"X Hu","year":"2024","unstructured":"Hu X, Wang P, Zeng D, Hu GX. The effect of gene polymorphism on ticagrelor metabolism: an\u00a0in vitro\u00a0study of 22 CYP3A4 variants in Chinese Han population. PeerJ. 2024;12:e18109. https:\/\/doi.org\/10.7717\/peerj.18109.","journal-title":"PeerJ"},{"issue":"10","key":"4092_CR39","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1002\/jps.23258","volume":"101","author":"FG Bahar","year":"2012","unstructured":"Bahar FG, Ohura K, Ogihara T, Imai T. Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci. 2012;101(10):3979\u201388. https:\/\/doi.org\/10.1002\/jps.23258.","journal-title":"J Pharm Sci"},{"key":"4092_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116128","volume":"223","author":"M Nagaoka","year":"2024","unstructured":"Nagaoka M, Sakai Y, Nakajima M, Fukami T. Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology. Biochem Pharmacol. 2024;223:116128. https:\/\/doi.org\/10.1016\/j.bcp.2024.116128.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4092_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41401-024-01407-4","volume":"46","author":"YG Wang","year":"2025","unstructured":"Wang YG, Gan CP, Beukers-Korver J, Rosing H, Li WL, Wagenaar E, et al. Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice. Acta Pharmacol Sin. 2025;46(3):777\u201393. https:\/\/doi.org\/10.1038\/s41401-024-01407-4.","journal-title":"Acta Pharmacol Sin"},{"key":"4092_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115304","volume":"166","author":"NHC Loos","year":"2023","unstructured":"Loos NHC, Retmana IA, Rijmers J, Wang Y, Gan C, Lebre MC, et al. Pharmacokinetics of the KRASG12C\u00a0inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c. Biomed Pharmacother. 2023;166:115304. https:\/\/doi.org\/10.1016\/j.biopha.2023.115304.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4092_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1006\/bbrc.1998.8809","volume":"247","author":"IM Janson","year":"1998","unstructured":"Janson IM, Toomik R, O\u2019Farrell F, Ek P. KDEL motif interacts with a specific sequence in mammalian erd2 receptor. Biochem Biophys Res Commun. 1998;247(2):447\u201351. https:\/\/doi.org\/10.1006\/bbrc.1998.8809.","journal-title":"Biochem Biophys Res Commun"},{"key":"4092_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/tcrm.s152369","volume":"14","author":"MJ Kubisa","year":"2018","unstructured":"Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postu\u0142a M. Ticagrelor - toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129\u201340. https:\/\/doi.org\/10.2147\/tcrm.s152369.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"4092_CR45","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2309300","volume":"23","author":"P Adamski","year":"2022","unstructured":"Adamski P, Skonieczny G, Hajdukiewicz T, Kern A, Kubic J. Reversal of platelet inhibition in patients receiving ticagrelor. Rev Cardiovasc Med. 2022;23(9):300. https:\/\/doi.org\/10.31083\/j.rcm2309300.","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"4092_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3810\/hp.2010.11.338","volume":"38","author":"P Capranzano","year":"2010","unstructured":"Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Hosp Pract. 2010;38(4):38\u201343. https:\/\/doi.org\/10.3810\/hp.2010.11.338.","journal-title":"Hosp Pract"},{"issue":"11","key":"4092_CR47","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/jth.12719","volume":"12","author":"K Hoffmann","year":"2014","unstructured":"Hoffmann K, Lutz DA, Stra\u00dfburger J, Baqi Y, M\u00fcller CE, von K\u00fcgelgen I. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12-receptor. J Thromb Haemost. 2014;12(11):1898\u2013905. https:\/\/doi.org\/10.1111\/jth.12719.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4092_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bph.16204","volume":"181","author":"J Khalil","year":"2024","unstructured":"Khalil J, Dimofte T, Roberts T, Keith M, Amaradasa K, Hindle MS, et al. Ticagrelor inverse agonist activity at the P2Y12\u00a0receptor is non-reversible versus its endogenous agonist adenosine 5\u00b4-diphosphate. Br J Pharmacol. 2024;181(1):21\u201335. https:\/\/doi.org\/10.1111\/bph.16204.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4092_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead076","volume":"3","author":"L De Luca","year":"2023","unstructured":"De Luca L, Calabr\u00f2 P, Capranzano P, Di Mario C, Chirillo F, Rolfo C, et al. Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study. European Heart Journal Open. 2023;3(4):oead076. https:\/\/doi.org\/10.1093\/ehjopen\/oead076.","journal-title":"European Heart Journal Open"},{"issue":"20","key":"4092_CR50","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/circulationaha.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12\u00a0receptor-inhibiting therapies. Circulation. 2017;136(20):1955\u201375. https:\/\/doi.org\/10.1161\/circulationaha.117.031164.","journal-title":"Circulation"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04092-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:30:49Z","timestamp":1781537449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04092-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04092-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}